Standout Papers

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinica... 2020 2026 2022 2024174
  1. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme (2020)
    Stanley Cohen, Ronald van Vollenhoven et al. Annals of the Rheumatic Diseases
  2. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis (2020)
    Andrea Rubbert‐Roth, Jeffrey Enejosa et al. New England Journal of Medicine

Citation Impact

1 from Science/Nature 113 standout
Sub-graph 1 of 18

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
A Gas Therapy Strategy for Intestinal Flora Regulation and Colitis Treatment by Nanogel‐Based Multistage NO Delivery Microcapsules
2024 Standout
18 intermediate papers

Works of Nasser Khan being referenced

Safety, Tolerability, and Pharmacodynamics of ABT ‐122, a Tumor Necrosis Factor– and Interleukin‐17–Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis
2017
A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy
2016
and 5 more

Author Peers

Author Rheumatology Hematology Genetics Immunology Last Decade Papers Cites
Nasser Khan 682 334 180 266 27 953
Kaoru Niki 31 20 8 97 21 473
M. Chandrachood 22 380
Yue Wang 16 303
Barbara N. Phenix 1 4 139 7 411
Rihong Cong 7 10 5 54 13 592

All Works

Loading papers...

Rankless by CCL
2026